CrossMark

Click-chemistry-based multicomponent condensation approach for design and synthesis of spirochromene-tethered 1,2,3-triazoles as potential antitubercular agents

Pramod V. Chavan[1] · Kapil S. Pandit[1] ·
Uday V. Desai[1] · Prakash P. Wadgaonkar[2] ·
Laxman Nawale[3] · Sujit Bhansali[3] · Dhiman Sarkar[3]

Abstract A series of spirochromene-tethered 1,2,3-triazoles (1,2,3-triazolyl-spirochromenes) were designed and synthesized via click-chemistry-based one-pot five-component reaction between N-propargyl isatins, malononitrile, dimedone (or 4-hydroxyl-6-methyl-2H-pyran-2-one), arylalkyl halides, and sodium azide using cellulose-supported CuI nanoparticles (Cell-CuI NPs) as heterogeneous catalyst. All synthesized compounds were screened for inhibitory activity against *Mycobacterium tuberculosis* H37Ra (ATCC 25177) and *Mycobacterium bovis* BCG (ATCC 35743), in active as well as dormant state. During screening, compounds **6h**, **j**, **l** were found to exhibit promising antimycobacterial activity against *M. bovis* BCG, while compounds **7d**, **h**, **l** showed promising antimycobacterial activity against *M. tuberculosis* H37Ra as well as *M. bovis* BCG. The active compounds were found to be noncytotoxic to three human cancer cell lines (MCF-7, HCT116, and A549). The active compounds exhibited selectivity index >10, indicating potential as antitubercular agents. The active compounds were also evaluated for in vitro antibacterial activity, with five (**6h**, **l**, **7b**, **f**, **l**) showing good antibacterial activity against Gram-positive as well as Gram-negative bacteria. Compounds **6h**, **j**, **l** exhibiting promising activity against *M. bovis* BCG can serve as good leads for further modification and optimization.

✉ Uday V. Desai
  uvdchem2011@gmail.com

[1] Department of Chemistry, Shivaji University, Kolhapur 416 004, India

[2] Polymer Science and Engineering Division, CSIR National Chemical Laboratory,
  Pune 411 008, India

[3] Combi Chem–Bio Resource Centre, CSIR National Chemical Laboratory, Pune 411 008, India

Introduction

Tuberculosis (TB) is an infectious disease caused by *Mycobacterium tuberculosis*, remaining one of the greatest health problems even in the 21st century [1, 2]. The main problem associated with spread of tuberculosis is emergence of strains resistant to one or more drugs and the very long time required for treatment of multiple-drug-resistant tuberculosis (MDR-TB) as well as extensively drug-resistant tuberculosis (XDR-TB) [3–6]. For the last few years, the combination of rifampicin, ethambutol, and isoniazid remains the effective therapy for treatment of TB [7] and as far as discovery of new, effective drugs to encounter TB is concerned, except bedaquiline, no remarkable breakthroughs have been achieved in the recent past. With the possibility that tubercular bacilli will acquire resistance to all these drugs, there is an urgent need to develop new antitubercular agents [8]. Amongst various approaches developed for introduction of new antitubercular agents, molecular hybridization involving design of new chemical entities by covalent fusion of two or more pharmacophores is an attractive strategy [9–12]. Synthesis of such hybrid molecules may involve separate synthesis of two or more subunits with known bioprofiles followed by their combination in a final step, or synthesis in a single step using a multicomponent synthesis strategy [13–17]. Amongst these approaches, the multicomponent condensation pathway is certainly advantageous in terms of atom economy, yield, selectivity, efficiency, and minimum waste generation [18]. With all these concepts in mind and our continued interest in multicomponent synthesis [19–25], we undertook synthesis of novel hybrid molecules as possible antitubercular agents.

It is well known that, owing to their diverse biological properties, heterocyclic compounds play a very important role in organic chemistry. Among various heterocyclic compounds, spiroheterocycles, especially spirooxindoles, represent a medicinally privileged scaffold present in many naturally occurring bioactive alkaloids (Fig. 1a) [26–29]. In recent years, spirooxindole derivatives fused with 2-amino-4*H*-chromene unit, viz. spirochromenes (Fig. 1b), have become immensely important due to their diuretic, spasmolytic, anticancer, anticoagulant, and antianaphylactic activities [30–32]. Like spirochromenes, compounds containing 1,2,3-triazole structural motif are also known to possess antitubercular, anticancer, antifungal, antiallergic, antiviral, antimicrobial, antiepileptic, as well as anti-human immunodeficiency virus (HIV) properties (Fig. 1c–f) [33–48]. Considering the biological potential of spirochromenes as well as of 1,2,3-triazoles, we surmised that hybrid molecules containing both of these structural units (Fig. 2) may possess enhanced antitubercular activity.

From the retrosynthetic viewpoint, synthesis of such hybrid molecules involves construction of the spirochromene motif in a first step then construction of the 1,2,3-triazole unit in a subsequent step, or vice versa. The best known pathway for synthesis of spirochromenes involves multicomponent condensation between isatin,

Fig. 1 Spirooxindole- and 1,2,3-triazole-containing bioactive compounds

Fig. 2 1,2,3-Triazolyl-spirochromene hybrid molecule

active methylene compound (malononitrile/alkyl cyanoacetate), and cyclic 1,3-dicarbonyl compound (dimedone, 4-hydroxyl-6-methyl-2*H*-pyran-2-one, etc.). Such condensation is reported to proceed under the influence of base as well as CuI as catalyst [49, 50]. On the other hand, copper-catalyzed azide–alkyne cycloaddition (CuAAC, click chemistry) remains the approach of choice for synthesis of 1,2,3-triazoles [51–55] (Scheme 1a, b).

Scheme 1 Retrosynthetic analysis for synthesis of spirochromenes and 1,2,3-triazoles

We previously reported cellulose-supported cuprous iodide nanoparticles (Cell-CuI NPs) as heterogeneous and reusable catalyst for synthesis of 1,4-disubstituted 1,2,3-triazoles [56] and recently also reported environmentally benign protocols for synthesis of 2-amino-4*H*-chromenes [19–21]. Based on these results, we speculated that, if cuprous iodide nanoparticles (Cell-CuI NPs) are effective for construction of spirochromene moiety, it would be possible to synthesize the targeted hybrid molecules using a one-pot five-component condensation approach. As an outcome of this philosophy, we report herein synthesis of spirochromene-tethered 1,2,3-triazoles by one-pot five-component condensation between *N*-propargyl isatins, malononitrile, dimedone (or 4-hydroxy-6-methyl-2*H*-pyran-2-one), arylalkyl halides, and sodium azide using Cell-CuI NPs as reusable catalyst (Scheme 2).

Results and discussion

Chemistry

The synthetic route started with preparation of *N*-propargyl isatins. Various substituted *N*-propargylated isatins were prepared by potassium-carbonate-catalyzed propargylation of isatins with propargyl bromide using dimethylformamide (DMF) as solvent and tetra-*n*-butylammonium bromide (TBAB) as phase-transfer catalyst [56].

We first focused on exploring the feasibility of using Cell-CuI NPs as catalyst for synthesis of spirochromenes. Accordingly, a model reaction was performed using *N*-propargyl isatin, malononitrile, and dimedone as substrates (Scheme 3). Thus, to an equimolar mixture of *N*-propargyl isatin, malononitrile, and dimedone (1 mmol, each) in ethanol (5 mL) were added Cell-CuI NPs (100 mg, 3.7 mol% CuI) followed by continuous stirring at ambient temperature for 12 h. We did not observe any appreciable reaction progress, so the reaction was continued under reflux condition. Timely analysis of the reaction mixture by thin-layer chromatography

Scheme 2 One-pot five-component synthesis of 1,2,3-triazolylspirochromenes **6**, **7**

Scheme 3 Cell-CuI NP-catalyzed synthesis of spirochromenes

(TLC) indicated formation of a new product in major quantity. Upon reaction completion, the resultant product was isolated, purified by column chromatography, and identified as the expected spirochromene, **A** (78%, Scheme 3). Our primary aim with this trial reaction was simply to check the feasibility of using Cell-CuI NPs in synthesis of spirochromenes; however, as the desired spirochromene **A** was obtained in acceptable yield (78%) during the trial reaction, no further attempts were made towards improving the yield of **A** (Scheme 3).

Encouraged by this initial success, we next planned to undertake one-pot synthesis of 1,2,3-triazolylspirochromene **6a** (Scheme 2, $R_1 = R_2 = H$) as model compound. Accordingly, to well-stirred solution of N-propargyl isatin, malononitrile, dimedone, benzyl bromide (1 mmol, each), and sodium azide (1.1 mmol) in ethanol (5 mL) were added Cell-CuI NPs (200 mg, 7.4 mol% CuI). Stirring was continued under reflux, and reaction progress monitored by TLC. Upon reaction completion followed by work-up as well as spectral analysis, we were pleased to note formation of expected 1,2,3-triazolylspirochromene **6a** in acceptable yield (72%). Thereafter, attempts were directed towards improving the yield of desired **6a**. In this context, the model reaction was repeated in different reaction media. It was observed that, in common organic solvents such as toluene, acetonitrile, as well as tetrahydrofuran, the yield of the desired product **6a,** remained nearly the same. However, with water, water–ethanol, as well as water–acetonitrile as reaction medium, significantly increased yield of desired **6a** was found (Table 1, entries 3, 7, 8). However, with these water-based reaction media, product isolation proved to be slightly cumbersome. Hence, the model reaction was then carried out in dimethylformamide–water (2:1, v/v) as mixed solvent system (Table 1, entries 9–11). This modification proved to be useful in terms of both yield as well as isolation of the desired product **6a** (Table 1, entry 9). The results summarized in Table 1 also reveal that use of less than the optimized amount of catalyst failed to furnish the desired product **6a** in the same yield (Table 1, entries 10, 11). It is noteworthy that, in absence of added catalyst, the reaction furnished desired product **6a** in low yield (35%).

Having established appropriate reaction conditions, we turned our attention to examine the generality of the reaction conditions. Thus, the benzyl bromide component of the model reaction was replaced by 4-methyl (**4b**), 4-fluoro (**4c**), and 4-chlorobenzyl bromide (**4d**). Under the optimized reaction conditions, corresponding 1,2,3-triazolylspirochromenes **6b–d** were produced in excellent yield (Table 2).

Table 1 Optimization of reaction conditions for one-pot synthesis of 1,2,3-triazolylspirochromene **6a**

| Entry	Solvent	Catalyst (mg)	Temp. (°C)	Time (h)	Yield[a] (%)
1	Ethanol	200	RT	6	70
2	Ethanol	200	Reflux	5	85
3	Water	200	80	6	84
4	Toluene	200	100	5	70
5	Acetonitrile	200	Reflux	5	75
6	Tetrahydrofuran	200	Reflux	6	60
7	Water–ethanol (1:1)	200	Reflux	5	86
8	Water–acetonitrile (1:1)	200	80	5	80
9	**Water + DMF (2:1)**	**200**	**70**	**2**	**92**
10	Water + DMF (2:1)	150	70	3	83
11	Water + DMF (2:1)	100	70	4	80

Reaction conditions: *N*-propargyl isatin, malononitrile, dimedone, benzyl bromide (1 mmol, each), NaN_3 (1.1 mmol), Cell-CuI NPs, solvent

[b] Yields refer to pure isolated product

To examine the scope of the reaction conditions, various *N*-propargylated isatins derived from 5-chloroisatin (**1b**), 5-bromoisatin (**1c**), and 5-fluoroisatin (**1d**) were then used. Once again, the reaction furnished expected 1,2,3-triazolylspirochromenes **6e–p** in acceptable yield (Table 2). Finally, the dimedone component in each successful reaction was replaced with 4-hydroxyl-6-methyl-2*H*-pyran-2-one (**3b**) (Scheme 2). Most gratifyingly, in each case, corresponding 1,2,3-triazolyl-spirochromenes **7a–p** were produced in acceptable yield (Table 2). In this multicomponent synthesis of 1,2,3-triazolylspirochromenes under the influence of copper catalyst, formation of the chromene unit precedes construction of the 1,2,3-triazole unit (TLC). A plausible mechanism for the formation of the desired 1,2,3-triazolylspirochromene is depicted in Fig. 3.

In heterogeneously catalyzed reactions, reusability as well as stability of the catalyst is of importance from both economic and environmental points of view. Hence, upon completion of the model reaction, the catalyst was separated by filtration, washed repeatedly with ethyl acetate as well as acetone, dried in air, and used in the next run with the same substrates. The recovered catalyst also furnished desired 1,2,3-triazolylspirochromene **6a** in nearly the same yield (Fig. 4). Subsequent studies on reusability of the catalyst revealed that the catalyst could be used for four consecutive cycles without appreciable change in the yield of the desired triazole **6a**.

In copper-catalyzed click synthesis of biologically active molecules, study of catalyst leaching is also of prime importance. Therefore, upon reaction completion followed by catalyst separation, resultant filtrate was analyzed by atomic absorption spectroscopy, revealing no detectable copper content.

Table 2 Cell-CuI NP-catalyzed synthesis of 1,2,3-triazolylspirochromenes **6**, **7**

Entry	N-Propargyl isatin (**1**)	1,3-Dicarbonyl compound (**3a, b**)	Arylalkyl bromide (**4**)	Product (**6, 7**)	Time (h)	Yield[a] (%)	M.p. (°C)
1	**1a**	**3a**	**4a**	**6a**	2	92	142–144
2	**1a**	**3a**	**4b**	**6b**	3	94	150–152
3	**1a**	**3a**	**4c**	**6c**	3	91	145–147
4	**1a**	**3a**	**4d**	**6d**	4	82	155–158
5	**1b**	**3a**	**4a**	**6e**	2	84	158–160
6	**1b**	**3a**	**4b**	**6f**	2	76	214–216
7	**1b**	**3a**	**4c**	**6g**	3	80	148–150
8	**1b**	**3a**	**4d**	**6h**	4	83	160–162
9	**1c**	**3a**	**4a**	**6i**	3	84	218–220
10	**1c**	**3a**	**4b**	**6j**	4	83	178–180
11	**1c**	**3a**	**4c**	**6k**	5	81	176–178
12	**1c**	**3a**	**4d**	**6l**	5	78	190–192
13	**1d**	**3a**	**4a**	**6m**	3	92	178–180
14	**1d**	**3a**	**4b**	**6n**	4	88	160–162
15	**1d**	**3a**	**4c**	**6o**	5	85	182–184
16	**1d**	**3a**	**4d**	**6p**	5	84	205–207
17	**1a**	**3b**	**4a**	**7a**	3	87	228–230
18	**1a**	**3b**	**4b**	**7b**	4	83	235–238
19	**1a**	**3b**	**4c**	**7c**	4	92	223–225
20	**1a**	**3b**	**4d**	**7d**	5	84	208–210
21	**1b**	**3b**	**4a**	**7e**	3	87	160–162
22	**1b**	**3b**	**4b**	**7f**	4	81	182–184
23	**1b**	**3b**	**4c**	**7g**	3	83	150–152
24	**1b**	**3b**	**4d**	**7h**	5	86	150–152
25	**1c**	**3b**	**4a**	**7i**	3	84	180–182
26	**1c**	**3b**	**4b**	**7j**	5	85	182–184
27	**1c**	**3b**	**4c**	**7k**	3	86	188–190
28	**1c**	**3b**	**4d**	**7l**	5	84	185–187
29	**1d**	**3b**	**4a**	**7m**	3	83	260–262
30	**1d**	**3b**	**4b**	**7n**	5	92	222–224
31	**1d**	**3b**	**4c**	**7o**	3	85	243–245
32	**1d**	**3b**	**4d**	**7p**	5	83	218–220

[a] Reaction conditions: N-propargyl isatin, malononitrile, dimedone or 4-hydroxy-6-methyl-2H-pyran-2-one, arylalkyl bromide (1 mmol, each), NaN$_3$ (1.1 mmol), Cell-CuI (7 mol%), water–DMF (2: 1, v/v, 6 mL), 70 °C

[b] Yields refer to pure isolated product

Fig. 3 Plausible mechanism for synthesis of 1,2,3-triazolylspirochromene


Fig. 4 Reusability of Cell-CuI catalyst

Biological evaluation

Antitubercular studies

As well as designing and synthesizing novel organic molecules, we also aimed to screen their antitubercular activity. Hence, all synthesized compounds were screened for in vitro antitubercular activity against *M. tuberculosis* H37Ra (MTB) (ATCC 25177) and *M. bovis* BCG (ATCC 35743) by twofold dilution technique. The minimum inhibitory concentration (MIC) and 50% inhibition concentration (IC_{50}) values of the tested compounds are presented in Table 3. Rifampicin, a drug in regular clinical use, was applied as reference standard. During primary screening, of 32 synthesized compounds, 20 were found to be active against both species with MIC in the range of 2.87–10.00 μg/mL (Table 3). In particular, compounds **6h**, **j**, **l** were found to be most active against *M. bovis* BCG (MIC from 2.87 to 6.23 μg/mL) in active as well as dormant state. On the other hand, compounds **7d**, **h**, **l** were found to be promisingly active (MIC < 7 μg/mL) against both *M. tuberculosis* H37Ra as well as *M. bovis* BCG. From the antimycobacterial activity data summarized in Table 3, it is evident that the activity depends upon the nature of the substituents R_1 and R_2 present on the phenyl rings. Replacement of hydrogen atoms on phenyl rings at R_1 and R_2 by halogen resulted in increased antitubercular activity. Amongst halogens, presence of chlorine substituent on phenyl as well as isatin ring proved to be useful for enhanced antitubercular activity. Regarding the choice of the 1,3-diketone, replacement of dimedone with 4-hydroxyl-6-methyl-2*H*-pyran-2-one did not cause any significant change in the antimycobacterial activity against *M. bovis* BCG, while for *M. tuberculosis* H37Ra it was increased to moderate extent.

Cytotoxicity

All synthesized compounds (**6a–7p**) were then evaluated for their in vitro cytotoxicity against three human cancer cell lines, viz. MCF-7, HCT116, and A549, by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay with paclitaxel as positive control [57–59]. The results are summarized in Table 4. The 50% growth inhibition concentration (GI_{50}) values (>100 μg/mL) of the active compounds **6a–7f**, **m–p** indicate that these compounds are potent and specific inhibitors of MTB. Especially **7g–l** were found to be active antiproliferative compounds with GI_{50} in the range of 22.08–71.68 μg/mL against MCF-7 cell line but not against HCT116 or A549.

GI_{50} values obtained from cytotoxicity studies allow calculation of the selectivity index, which reflects the concentration of a compound at which it is active against mycobacteria but not toxic towards host cells. Higher selectivity index indicates that the compound can be used as a therapeutic agent. The selectivity of triazolyl-spirochromenes **6a–7p** towards human cell lines and against *M. bovis* BCG was therefore described in terms of the selectivity index, and the results are presented in

Table 3 Antimycobacterial activity of various 1,2,3-triazolylspirochromenes

Entry	R$_1$	R$_2$	M. tuberculosis H37Ra				M. bovis BCG			
			Active stage		Dormant stage		Active stage		Dormant stage	
			MIC	IC$_{50}$	MIC	IC$_{50}$	MIC	IC$_{50}$	MIC	IC$_{50}$
6a	H	H	>30	25.64	>30	27.81	28.22	7.8	26.56	8.43
6b	H	Me	>30	>30	>30	>30	>30	>30	>30	>30
6c	H	F	>30	>30	>30	>30	28.88	16.44	27.64	13.75
6d	H	Cl	49.15	18.96	23.16	12.4	8.98	3.6	8.97	4.26
6e	Cl	H	>30	29.43	>30	29.59	27.43	18.49	26.82	16.93
6f	Cl	Me	>50	22.65	21.47	11.11	8.15	1.67	9.24	4.2
6g	Cl	F	39.61	17.25	23.96	17.36	6.60	3.2	9.44	3.45
6h	**Cl**	**Cl**	>50	15.45	**8.07**	**3.06**	**2.87**	**1.33**	**3.09**	**0.6**
6i	Br	H	39.79	5.86	13.48	7.06	7.87	3.47	4.66	2.06
6j	**Br**	**Me**	29.23	3.24	**8.89**	**5.1**	**2.87**	**1.33**	**6.23**	**1.33**
6k	Br	F	46.35	29.81	10.33	5.38	7.28	3.17	8.09	2.42
6l	**Br**	**Cl**	>50	22.81	**10.60**	**5.89**	**4.32**	**1.8**	**3.16**	**1.24**
6m	F	H	>30	27.56	>30	25.93	18.09	3.78	19.39	4.73
6n	F	Me	>50	29.23	26.59	14.05	10.96	4.13	18.69	4.63
6o	F	F	34.30	13.39	16.17	8.33	>50	13.65	23.91	3.25
6p	F	Cl	>30	15.62	>30	17.65	12.37	5.34	13.86	5.34
7a	H	H	>30	16.53	>30	15.19	27.54	15.46	26.48	16.76
7b	H	Me	13.99	2.13	7.3	1.71	7.42	1.68	5.36	1.97
7c	H	F	27.7	4.31	16.16	4.53	7.51	2.91	10.13	3.25
7d	**H**	**Cl**	**5.21**	**1.63**	**4.39**	**1.43**	**2.97**	**0.7**	**4.35**	**2.06**
7e	Cl	H	37.35	18.2	23.09	13.93	13.07	5.53	5.74	1.42
7f	Cl	Me	>50	17.67	11.59	7.93	5.24	2.53	5.23	1.26
7g	Cl	F	>50	42.06	11.18	6.6	8.04	2.42	6.69	1.14
7h	**Cl**	**Cl**	**5.39**	**1.84**	**4.81**	**2.32**	**3.04**	**0.45**	**7.73**	**1.56**
7i	Br	H	>30	14.63	>30	21.31	5.93	2.36	10.45	4.21
7j	Br	Me	>30	6.39	>30	6.21	10.39	5.8	9.71	5.11
7k	Br	F	26.27	4.72	26.77	7.01	6.82	2.67	6.14	2.61
7l	**Br**	**Cl**	**6.63**	**2.71**	**6.8**	**3.07**	**4.12**	**2.11**	**3.97**	**1.14**
7m	F	H	30	28.72	30	28.78	30	17.53	>30	15.61
7n	F	Me	29.56	3.56	28.93	6.15	>30	9.41	>30	9.17
7o	F	F	>30	>30	>30	>30	>30	18.57	>30	17.39
7p	F	Cl	8.81	4.47	4.5	8.88	23.12	5.14	17.04	4.57
Rifampicin			0.51	0.002	0.75	0.05	0.45	0.005	0.81	0.075

MIC minimum inhibitory concentration, *IC$_{50}$* 50% inhibitory concentration

Table 5. It is evident that compounds **6h**, **j**, **l**, **7b**, **d**, **h**, **l** exhibited selectivity index value >10, indicating potential as antitubercular agents, thus they should be investigated further as possible anti-TB agents.

Table 4 In vitro cytotoxicity profile of selected 1,2,3-triazolylspirochromenes against three human cancer cell lines

Product code	MCF-7 GI_{50} (µg/mL)	HCT116 GI_{50} (µg/mL)	A549 GI_{50} (µg/mL)
6a–7f	>100	>100	>100
7g	**43.22**	>100	>100
7h	**71.68**	>100	>100
7i	**22.08**	>100	>100
7j	**29.12**	>100	>100
7k	**41.73**	>100	>100
7l	**48.57**	>100	>100
7m–p	>100	>100	>100
Rifampicin	>100	>100	>100
Paclitaxel	0.0048	0.026	0.0035

GI_{50} 50% growth inhibition concentration

Table 5 Selectivity index (SI) of the most active compounds **6h**, **j**, **l**, **7d**, **h**, **l** against active as well as dormant *M. BCG* vs. three human cancer cell lines

Product	MIC against *M. bovis* BCG (mg/mL)		SI against MCF-7 (breast)		SI against HCT116 (colon)		SI against A549 (lung)	
	Active state	Dormant state	Active state	Dormant state	Active state	Dormant state	Active state	Dormant state
6h	2.87	3.09	35	32	35	32	35	32
6j	2.87	6.23	35	16	35	16	35	16
6l	4.32	3.16	23	32	23	32	23	32
7b	7.42	5.36	13	19	13	19	13	19
7d	2.97	4.35	34	23	34	23	34	23
7h	3.04	7.73	24	09	33	13	33	13
7l	4.12	3.97	12	12	24	25	24	25
Rif	0.45	0.81	222	123	222	123	222	123

Rif rifampicin

Antibacterial studies

Escherichia coli, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and *Bacillus subtilis* are common pathogens that have harmful effects on human health. We thought it worthwhile to evaluate the antimicrobial activity of 1,2,3-triazolyl-spirochromenes against these microorganisms [60]. This assay was performed by well plate method (zone of inhibition) using ampicillin and kanamycin as reference standards. The results are summarized in Table 6 (ESI, Table S6). Five compounds (**6h**, **l**, **7b**, **f**, **l**) showed more than 90% inhibition at concentration of 3 µg/mL. Compounds showing good antibacterial activity were further analyzed to determine MIC values using dose–response curves. Compounds **6h**, **l**, **7b**, **f**, **l** showed good antibacterial activity against *E. coli*, *P. aeruginosa*, *S. aureus*, and *B. subtilis*, with MIC values varying from 1.1 to 5.29 µg/mL.

Table 6 In vitro antibacterial activity of 1,2,3-triazolylspirochromenes against *E. coli*, *S. aureus*, *P. aeruginosa*, and *B. subtilis*

Product code	Gram negative		Gram positive	
	E. coli MIC_{90} (μg/mL)	*P. aeruginosa* MIC_{90} (μg/mL)	*S. aureus* MIC_{90} (μg/mL)	*B. subtilis* MIC_{90} (μg/mL)
6h	**1.78**	**5.29**	**3.55**	**1.14**
6j	>30	>30	>30	>30
6l	**2.86**	**1.57**	**1.09**	**3.18**
7b	**1.97**	**3.08**	**4.27**	**2.85**
7d	29.89	26.28	>30	26.15
7f	**2.65**	**4.88**	**2.41**	**7.19**
7h	>30	>30	>30	>30
7l	**2.75**	**2.33**	**3.86**	**5.27**
Amp.	1.46	4.36	1	10.32
Kana.	1.62	0.49	>30	1.35

Amp ampicillin, *Kana* kanamycin

All the results above clearly indicate that target compound **6h** is mycobacteria specific and can be further explored as a potential antitubercular drug.

Conclusions

Based on the structure of compounds with proven biological activity and our experience in click chemistry, green chemistry, and multicomponent reactions, studies were undertaken on the design and one-pot synthesis of novel compounds as possible antitubercular agents. We designed and synthesized for the first time a series of 1,2,3-triazolylspirochromenes by one-pot five-component condensation between *N*-propargyl isatin, malononitrile, dimedone (or 4-hydroxyl-6-methyl-2*H*-pyran-2-one), arylalkyl halide, and sodium azide using cellulose-supported CuI nanoparticles (Cell-CuI NPs) as heterogeneous catalyst. Simple experimental procedure, wide scope, and catalyst reusability for five consecutive runs are the main merits of this ecobenign protocol. The synthesized compounds were screened for their antimycobacterial activity. Among all the compounds, **6h**, **j**, **l** showed very good antimycobacterial activity against *M. bovis* BCG. Some of the synthesized 1,2,3-triazolylspirochromenes (**7d**, **h**, **l**) showed promising antimycobacterial activity against *Mycobacterium tuberculosis* H37Ra as well as *M. bovis* BCG. The active compounds were found to be noncytotoxic to three cell cancer lines. Selectivity studies revealed that these active compounds have potential as possible antitubercular agents. The specificity of these compounds was checked by screening their antibacterial activity against four bacterial strains. Compounds **6h**, **l**, **7b**, **f**, **l** showed good antibacterial activity. All the above screening results clearly indicate that 1,2,3-triazolylspirochromenes can be further explored as potential antitubercular drugs via chemical modification.

Appendix

Experimental

General

Isatins (Aldrich), benzyl halides (Aldrich), sodium azide (S. D. Fine-Chem. Limited, Mumbai), dimedone, malononitrile, copper(I) iodide (Spectrochem, Mumbai), and microcrystalline cellulose (SRL, Mumbai) were used as received. Cell-CuI NPs as catalyst were prepared according to the procedure developed and reported by us earlier [56]. All melting points were recorded using Kumar melting point apparatus. Infrared (IR) spectra were recorded neat using a Thermo Scientific Nicolet iS10 FT-IR spectrometer. ^{1}H nuclear magnetic resonance (NMR) (300 MHz) and ^{13}C NMR (75.4 MHz) spectra were recorded using Bruker Avance II spectrometer. High-resolution mass spectra (HRMS) were recorded using Thermo Scientific Q-Exactive, Accela 1250 pump, instrument.

Representative procedure for one-pot synthesis of 1,2,3-triazolylspirochromenes

N-Propargyl isatin (1 mmol), malononitrile (1 mmol), dimedone (1 mmol), benzyl bromide (1 mmol), and sodium azide (1.1 mmol) were placed in a round-bottomed flask. DMF–water (1:2, 6 mL, v/v) and cellulose-CuI NPs as catalyst (0.2 g) were added, and the reaction mixture was heated at 70 °C. After reaction completion (TLC), the reaction mixture was filtered and the filter was washed with ethyl acetate (4 × 10 mL). The organic extract was washed with water and brine and dried over Na_2SO_4. Removal of solvent under vacuum furnished corresponding 1,4-disubstituted 1,2,3-triazolylspirochromene as solid product. The resultant solid was successively washed using a mixture of hexane–chloroform (80: 20 v/v), and dried. None of the resultant products required any further purification. The recovered catalyst was washed with acetone, dried in air, and reused for five consecutive runs.

Biological methods

Antimycobacterial activity

All synthesized compounds were screened for their in vitro activity against *M. tuberculosis* H37Ra (MTB) (ATCC 25177) and *M. bovis* BCG (ATCC 35743) using twofold dilution technique to determine the minimum inhibitory concentration (MIC). Screening against *M. tuberculosis* H37Ra was carried out by XTT reduction menadione assay (XRMA) by reading the absorbance at 470 nm, while screening of *M. bovis* BCG was carried out by nitrate reductase (NR) assay [61–63]. The optical

density was read on a microplate reader using a 470-nm filter for XTT and a 540-nm filter for NR against blank prepared from cell-free wells. Absorbance given by cells treated with vehicle alone was taken as 100% cell growth. Initially, primary screening was done at 30, 10, and 3 μg/ml. Compounds showing 90% inhibition of bacilli at or lower than 30 μg/ml were selected for further dose–response curve analysis. All experiments were performed in triplicate, with values expressed as average ± standard deviation. MIC and IC_{50} values of selected compounds were calculated from dose–response curves using Origin 6 software. Percentage inhibition was calculated using the formula: % inhibition = [(control − CMP)/(control − blank)] × 100, where "control" is the activity of mycobacteria without compounds, "CMP" is the activity of mycobacteria in presence of compound, and "blank" is the activity of culture medium without mycobacteria.

Cytotoxicity and selectivity index

To check the selectivity, all compounds were assayed for their cytotoxic effects against three different cell lines (MCF-7, A549, and HCT116) by MTT assay (Table 4) [64–66]. The cell lines were maintained at 37 °C under 5% CO_2/95% air humidified environment. The concentration range for each compound was selected as 30, 10, and 3 μg/mL. Each concentration was tested in duplicate in a single experiment. GI_{50} and MIC values were calculated using OriginPro software. Viability and growth in presence of test material were calculated using the following formula: % cytotoxicity = [(average absorbance of control − absorbance of compound)/(absorbance of control − absorbance of blank)] × 100, where control is the culture medium with cells and dimethyl sulfoxide (DMSO), and blank is the culture medium without cells. The selectivity index (SI) was calculated by dividing the 50% growth inhibition concentration (GI50) value for each cell line (MCF-7, A549, and HCT116) by the MIC for in vitro activity against active/dormant MTB and BCG [60].

Antibacterial activity

All bacterial cultures were first grown in Luria-Bertani (LB) medium at 37 °C at 180 RPM. Once the culture reached 1 OD, it was used for antibacterial assay. Bacterial strains *E. coli* (NCIM 2688), *P. aeruginosa* (NCIM 2036) as Gram-negative and *B. subtilis* (NCIM 2079), *S. aureus* (NCIM 2010) as Gram-positive strains were obtained from NCIM (NCL, Pune) and grown in Luria-Bertani medium. Screening was carried out by adding 0.1% 1-OD inoculated culture to each well of a 96-well plate containing the compounds to be tested and measuring the optical density at 620 nm after 8 h for Gram-negative or 12 h for Gram-positive bacteria.

References

1. B.H. Herzog, Respiration **65**, 5 (1998)
2. Global Tuberculosis Control: WHO report 2014

3. R.P. Tripathi, N. Tewari, N. Dwivedi, V.K. Tiwari, Med. Res. Rev. **25**, 93 (2005)
4. D.-B. Young, M.D. Perkin, K. Duncanan, C.E. Barry, J. Clin. Invest. **118**, 1255 (2008)
5. C. Lienhardt, A. Vernon, M.C. Raviglione, Curr. Opin. Pulm. Med. **16**, 186 (2010)
6. M.M. Sankar, J. Singh, S.C.A. Diana, S. Singh, Tuberculosis **93**, 75 (2013)
7. M.M. Singh, Indian J. Tuberc. **54**, 1 (2007)
8. L.T. Nao, J.J. Okogun, W.R. Folk, Nat. Prod. Rep. **30**, 584 (2013)
9. R. Maia, C. Do, C.A.M. Fraga, Curr. Enzyme Inhib. **6**, 171 (2010)
10. C. Viegas-Junior, A. Danuello, V. da Silva Bolzani, E.J. Barreiro, C.A.M. Fraga, Curr. Med. Chem. **14**, 1829 (2007)
11. C.A.M. Fragae, Drug. Discov. **4**, 605 (2009)
12. E.M. Guantai, K. Ncokazi, T.J. Egan, J. Gut, P.J. Rosenthal, P.J. Smith, K. Chibale, Bioorg. Med. Chem. **18**, 8243 (2010)
13. K. Kurnaravel, G. Vasuki, Curr. Org. Chem. **13**, 1820 (2009)
14. M. Syamala, Org. Prep. Proced. Int. **41**, 1 (2009)
15. A. Dömling, W. Wang, K. Wang, Chem. Rev. **112**, 3083 (2012)
16. V.A. Gulevich, G.A. Zhdanko, V.A.O. Romano, G.V. Nenajdenko, Chem. Rev. **110**, 5235 (2010)
17. C. De Graaff, E. Ruijter, R.V. Orru, Chem. Soc. Rev. **41**, 3969 (2012)
18. J.E. Biggs- Houck, A. Younai, J.T. Shaw, Curr. Opin. Chem. Biol. **14**, 371 (2010)
19. K.S. Pandit, R.V. Kupwade, P.V. Chavan, U.V. Desai, P.P. Wadgaonkar, K.M. Kodam, ACS Sustain. Chem. Eng. **4**, 3450 (2016)
20. K.S. Pandit, P.V. Chavan, U.V. Desai, M.A. Kulkarni, P.P. Wadgaonkar, New J. Chem. **39**, 4452 (2015)
21. M.A. Kulkarni, V.R. Pandurangi, U.V. Desai, P.P. Wadgaonkar, C. R. Chim. **15**(9), 745 (2012)
22. A.M. Kulkarni, K.S. Pandit, P.V. Chavan, U.V. Desai, P.P. Wadgaonkar, RSC Adv. **5**, 70586 (2014)
23. K.S. Pandit, P.V. Chavan, U.V. Desai, M.A. Kulkarni, P.P. Wadgaonkar, New J. Chem. **39**, 4452 (2015)
24. S.D. Mitragotri, D.M. Pore, U.V. Desai, P.P. Wadgaonkar, Catal. Commun. **9**, 1822 (2008)
25. D.M. Pore, U.V. Desai, T.S. Thopate, P.P. Wadgaonkar, Aust. J. Chem. **60**, 435 (2007)
26. J.F.M. da Silva, S.J. Garden, A.C. Pinto, J. Braz. Chem. Soc. **12**, 273 (2001)
27. A.E. Medvedev, A. Clow, M. Sandler, V. Glover, Biochem. Pharmacol. **52**, 385 (1996)
28. M. Yamazaki, E. Okuyama, Tetrahedron Lett. **22**, 135 (1981)
29. A. Dandia, R. Singh, S. Khauria, C. Merienne, G. Morgant, A. Loupy, Bioorg. Med. Chem. **14**, 2409 (2006)
30. J. Skommer, D. Wlodkowic, M. Matto, M. Eray, J. Pelkonen, Leuk. Res. **30**, 322 (2006)
31. N. Yu, J.M. Aramini, M.W. Germann, Z. Huang, Tetrahedron Lett. **41**, 6993 (2000)
32. L. Bonsignore, G. Loy, D. Secci, A. Calignano, Eur. J. Med. Chem. **28**, 517 (1993)
33. V.V. Rostovtsev, L.G. Green, V.V. Fokin, K.B. Sharpless, Angew. Chem. **114**, 2708 (2002)
34. V.V. Rostovtsev, L.G. Green, V.V. Fokin, K.B. Sharpless, Angew. Chem. Int. Ed. **41**, 2596 (2002)
35. C.W. Tornøe, C. Christensen, M. Meldal, J. Org. Chem. **67**, 3057 (2002)
36. N. Boechat, V.F. Ferreira, S.B. Ferreira, M.D.L.G. Ferreira, FdC da Silva, M.M. Bastos, M.D.S. Costa, M.C.S. Lourenço, A.C. Pinto, A.U. Krettli, A.C. Aguiar, B.M. Teixeira, N.V. da Silva, P.R.C. Martins, F.A.F.M. Bezerra, A.L.S. Camilo, G.P. da Silva, C.C.P. Costa, J. Med. Chem. **54**, 5988 (2011)
37. S.R. Patpi, L. Pulipati, P. Yogeeswari, D. Sriram, N. Jain, B. Sridhar, R. Murthy, T. Anjana Devi, S.V. Kalivendi, S. Kantevari, J. Med. Chem. **55**, 3911 (2012)
38. R.J. Naik, M.V. Kulkarni, K.S.R. Pai, P.G. Nayak, Chem. Biol. Drug Des. **80**, 516–523 (2012)
39. F. Mir, S. Shaf, M.S. Zaman, N.P. Kalia, V.S. Rajput, C. Mulakayal, N. Mulakayala, I.A. Khan, M.S. Alam, Eur. J. Med. Chem. **76**, 274 (2014)
40. D. Kumar, G. Beena, S. Khare, A.K. Kidwai, R. Tyagi, D.S.Rawat Singh, Eur. J. Med. Chem. **81**, 301 (2014)
41. D. Addla, A. Jallapally, D. Gurram, P. Yogeeswari, D. Sriram, S. Kantevari, Bioorg. Med. Chem. Lett. **24**, 1974 (2014)
42. M.H. Shaikh, D.D. Subhedar, L. Nawale, D. Sarkar, F.A. Kalam Khan, J.N. Sangshetti, B.B. Shingate, Med. Chem. Commun. **6**, 1104 (2015)
43. J.M. Altimari, S.C. Hockey, H.I. Boshoff, A. Sajid, L.C. Henderso, ChemMedChem **10**, 787 (2015)
44. T. Lee, M. Cho, S.Y. Ko, H.J. Youn, D.J. Baek, W.J. Cho, C.Y. Kang, S. Kim, J. Med. Chem. **50**, 585 (2007)
45. Y. Xia, Z. Fan, J. Yao, Q. Liao, W. Li, F. Qu, L. Peng, Bioorg. Med. Chem. Lett. **16**, 2693 (2006)

46. Y.-C. Duan, Y.-C. Ma, E. Zhang, X.-J. Shi, M.-M. Wang, X.-W. Ye, H.-M. Liu, Eur. J. Med. Chem. **62**, 11 (2013)
47. Y. Zhang, Z. Lv, H.A. Zhong, D. Geng, M. Zhang, T. Zhang, Y. Li, K. Li, Eur. J. Med. Chem. **53**, 356 (2012)
48. G.I. Wei, W. Luan, S. Wang, S. Cui, F. Li, Y. Liu, Y. Liu, M. Cheng, Org. Biomol. Chem. **13**, 1507 (2015)
49. K. Rad-Moghadam, L. Youseftabar-Miri, Tetrahedron **67**, 5693 (2011)
50. Z. Jamshidi, A.A. Esmaeili, J.T. Mague, J. Chem. Res. **40**, 471 (2016)
51. S.A. Bakunov, S.M. Bakunova, T. Wenzler, M. Ghebru, K.A. Werbovetz, R. Brun, R.R. Tidwell, J. Med. Chem. **53**, 254 (2010)
52. H. Singh, J. Sindhu, J.M. Khurana, C. Sharma, K.R. Aneja, Eur. J. Med. Chem. **77**, 145 (2014)
53. P. Thirumurugan, D. Matosiuk, K. Jozwiak, Chem. Rev. **113**, 4905 (2013)
54. S.G. Agalave, S.R. Maujan, V.S. Pore, Chem. Asian J. **6**, 269 (2011)
55. R. Berg, B.F. Straub, Beilstein J. Org. Chem. **9**, 2715 (2013)
56. P.V. Chavan, K.S. Pandit, U.V. Desai, M.A. Kulkarni, P.P. Wadgaonkar, RSC Adv. **4**, 42137 (2014)
57. T. Mosmann, J. Immunol. Methods **65**(1–2), 55 (1983)
58. G. Ciapetti, E. Cenni, L. Pratelli, A. Pizzoferrato, Biomaterials **14**, 359 (1993)
59. D. Sreekanth, A. Syed, S. Sarkar, D. Sarkar, B. Santhakumari, A. Ahmad, I. Khan, J. Microbiol. Biotechnol. **19**, 1342 (2009)
60. R. Singh, L.U. Nawale, M. Arkile, U.U. Shedbalkar, S.A. Wadhwani, D. Sarkar, B.A. Chopade, Int. J. Antimicrob. Agents **46**(2), 183 (2015)
61. U. Singh, S. Akhtar, A. Mishra, D. Sarkar, J. Microbiol. Methods **84**(2), 202 (2011)
62. A. Khan, D. Sarkar, J. Microbiol. Methods **73**, 62 (2008)
63. S. Sarkar, D. Sarkar, J. Biomol. Screen. **17**(7), 966 (2012)
64. M. Protopopova, C. Hanrahan, B. Nikonenko, R. Samala, P. Chen, J. Gearhart, L. Einck, C.A. Nacy, J. Antimicrob. Chemother. **56**, 968 (2005)
65. M. Poggi, R. Barroso, A.J. Costa-Filho, H.B. de Barros, F. Pavan, C.Q. Leite, D. Gambino, M.H. Torre, J. Mex. Chem. Soc. **57**, 198 (2013)
66. L.L. Gundersen, J. Nissen-Meyer, B. Spilsberg, J. Med. Chem. **45**, 1383 (2002)